Patent classifications
A61K31/635
Composition comprising amino acid polymers and a bioactive agent and method of preparing thereof
A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).
Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
A method of treating an asthmatic subject is provided. The method includes determining serum level of serum amyloid A (SAA) in the subject; comparing the serum level with a pre-determined threshold; and administering to the subject a therapeutically effective amount of a COX-2 inhibitor if the serum level is greater than or equal to the threshold.
Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
A method of treating an asthmatic subject is provided. The method includes determining serum level of serum amyloid A (SAA) in the subject; comparing the serum level with a pre-determined threshold; and administering to the subject a therapeutically effective amount of a COX-2 inhibitor if the serum level is greater than or equal to the threshold.
Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
A method of treating an asthmatic subject is provided. The method includes determining serum level of serum amyloid A (SAA) in the subject; comparing the serum level with a pre-determined threshold; and administering to the subject a therapeutically effective amount of a COX-2 inhibitor if the serum level is greater than or equal to the threshold.
SHORT CONJUGATED OLIGOELECTROLYTESAND ANTIBIOTICS
Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.
SHORT CONJUGATED OLIGOELECTROLYTESAND ANTIBIOTICS
Disclosed herein are combinations that include one or more conjugated oligoelectrolyte compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and one or more antibiotics. Combination of one or more conjugated oligoelectrolyte compounds and one or more antibiotics can potentiate the activity of the one or more antibiotics. Also disclosed are methods treating, reducing the severity of and/or slowing the progression of a bacterial infection, such as Gram-positive and Gram-negative bacteria, using a combination described herein.
Promotion of epithelial repair
There is provided a method for promoting epithelium repair in a subject, the method comprising administering to the subject a therapeutically effective amount of an activator of PI3K/Akt signalling.
Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS)
A pharmaceutical composition contains at least one methacrylic copolymer having units derived from methacrylamide; at least one pharmaceutically active ingredient; at least one lipid component; and at least one surfactant. The pharmaceutical composition can be used as a medicament. A method can be used to prepare a solid self-nanoemulsifying drug delivery system using the different compounds of the pharmaceutical composition.
Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS)
A pharmaceutical composition contains at least one methacrylic copolymer having units derived from methacrylamide; at least one pharmaceutically active ingredient; at least one lipid component; and at least one surfactant. The pharmaceutical composition can be used as a medicament. A method can be used to prepare a solid self-nanoemulsifying drug delivery system using the different compounds of the pharmaceutical composition.
SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXIS
Disclosed herein are methods of treating or preventing vector-borne diseases including Lyme disease via delivery of one, two, or more systemic doses of an isoxazoline anti-parasitic therapeutic agent to an individual with confirmed or suspected infestation of Lyme disease.